We are Fulfilling Unmet Needs in Pulmonary Medicine.

Aradigm is an emerging specialty pharmaceutical company developing and commercializing a portfolio of drugs delivered by inhalation for the treatment of severe respiratory disease.

Bolstered by its depth of expertise in pulmonary drug delivery and an extensive intellectual property portfolio, the Company is uniquely positioned to fulfill unmet needs in pulmonary medicine. Our corporate strategy includes the following:

• Continued development of proprietary respiratory disease therapies

• Pursue regulatory pathways that reduce the time, costs and risks associated with product development

• Conservation of capital for proprietary product development through the outsourcing of late stage clinical and commercial scale manufacturing

• Deployment of a specialized sales and marketing force to meet the unique needs of pulmonologists in the United States

• Out-licensing technology and intellectual property assets for applications that lie outside the company's strategic interests and core expertise

News & Events

Aradigm Announces Second Quarter 2017 Financial Results
[27JUL17]

Aradigm Submits New Drug Application (NDA) to FDA for U.S. Marketing Approval of Linhaliq in Non-Cystic Fibrosis Bronchiectasis
[27JUL17]

2nd World Bronchiectasis Conference Presentation - Charles Haworth Linhaliq BE

2nd World Bronchiectasis Conference Poster - Linhaliq WBE17 ORBIT Micro

2nd World Bronchiectasis Conference Poster - Linhaliq WBE17 ORBIT PK

Inhaled Liposomal Ciprofloxacin in Patients With Non-Cystic Fibrosis Bronchiectasis Presentation
[22MAY17]

 More News >>